Assenagon Asset Management
KROS icon

Assenagon Asset Management’s Keros Therapeutics KROS Stock Holding History

Assenagon Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-257,518
Closed -$4.07M – 1212
2025
Q3 		$4.07M Buy
257,518
+156,221
+154% +$2.31M 0.01% 654
2025
Q2 		$1.35M Buy
101,297
+36,360
+56% +$491K ﹤0.01% 866
2025
Q1 		$662K Hold
64,937
– – ﹤0.01% 965
2024
Q4 		$1.03M Sell
64,937
-158,767
-71% -$8.25M ﹤0.01% 1098
2024
Q3 		$13M Buy
223,704
+199,245
+815% +$9.84M 0.02% 465
2024
Q2 		$1.12M Buy
+24,459
New +$1.31M ﹤0.01% 1074

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Assenagon Asset Management's KROS Position: Q4 2025 in Review

Assenagon Asset Management sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 257,518 shares — an estimated $4.07M sold.

Assenagon Asset Management first reported a position in KROS in Q2 2024 and held it in 6 quarters. The position peaked at $13M in Q3 2024. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

  • Assenagon Asset Management reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 257,518 Keros Therapeutics shares in Q4 2025, an estimated $4.07M.
  • Assenagon Asset Management first reported a position in Keros Therapeutics in Q2 2024 and held it in 6 quarters.
  • Assenagon Asset Management's Keros Therapeutics position peaked at $13M in Q3 2024.
  • 166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on Assenagon Asset Management's 13F filing for Q4 2025, filed 9 Jan 2026.